RT Journal Article
SR Electronic
T1 SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases – data from the National Pediatric Rheumatology Database in Germany
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.28.21254496
DO 10.1101/2021.03.28.21254496
A1 Claudia Sengler
A1 Sascha Eulert
A1 Martina Niewerth
A1 Kirsten Minden
A1 Gerd Horneff
A1 Jasmin B. Kuemmerle-Deschner
A1 Caroline Siemer
A1 Rainer Berendes
A1 Hermann Girschick
A1 Regina Hühn
A1 Michael Borte
A1 Anton Hospach
A1 Wolfgang Emminger
A1 Jakob Armann
A1 Ariane Klein
A1 Tilmann Kallinich
YR 2021
UL http://medrxiv.org/content/early/2021/03/31/2021.03.28.21254496.abstract
AB Objectives Due to their underlying disease as well as therapeutic immunosuppression, children and adolescents with rheumatic and musculoskeletal diseases (RMD) may be at higher risk for a severe course or worse outcome of COVID-19, and SARS-CoV2 infection may trigger a flare of the RMD. To address these issues, a specific SARS-CoV-2 questionnaire was implemented in the National Pediatric Rheumatology Database (NPRD) in Germany.Methods Demographic, clinical and treatment data from juvenile patients with RMD as well as data about SARS-CoV-2 infection like test date and method, clinical characteristics, disease course, outcome and impact on the disease activity of the RMD documented on this questionnaire were analyzed.Results From April 17th, 2020, to February 14th, 2021, data were collected from 79 patients (53% female) with RMD with median age of 14 years, diagnosed with juvenile idiopathic arthritis (57%), autoinflammatory (23%) and connective tissue disease (8%). Sixty-one patients (77%) received disease-modifying antirheumatic drugs (DMARDs), 43% biologic DMARDs, and 9% systemic glucocorticoids. Sixty patients (76%) developed symptoms of COVID-19. Disease severity was mild and outcome was good in the majority of patients. Two patients were hospitalized, one of whom required intensive care and died of cardiorespiratory failure. In 84% of SARS-CoV-2-positive patients, no relevant increase in disease activity of the RMD was observed.Conclusions In our cohort, COVID-19 in juvenile patients with RMD under various medications was mild with good outcome in the majority of cases. SARS-CoV-2 infection does not appear to have a relevant impact on disease activity of the underlying condition.Competing Interest StatementC Sengler, none; S Eulert, none; M Niewerth, none; K Minden has received honoraria (< US$10.000) from AbbVie, Biermann, Chugai, Medac and Roche; G Horneff has received honoraria from Novartis, Chugai, Boeringer, Celgene and BMS and research grants from AbbVie, Chugai, MSD, Novartis, Pfizer and Roche; J B Kuemmerle-Deschner has no conflict of interest in regard to this study; C Siemer, none; R Berendes, none; H Girschick, none; R Huehn, none; M Borte, none; A Hospach has received consulting fees, speaking fees and/or honoraria from Chugai and Novartis (< US$10,000 each); W Emminger, none; J Armann, none, A Klein has received congress travel fees from Sobi, Sandoz and advisory board honoraria from Celgene; T Kallinich has no conflict of interest in regard to this study.Funding StatementThe National Paediatric Rheumatological Database has been funded by AbbVie, Chugai, GSK and Novartis. The BIKER registry has been supported by an unrestricted grant from Pfizer, Germany, Abbvie, Germany,Novartis, Germany and Roche, Germany. The COVID-19 Survey is supported by a grant by the Federal State of Saxony. The funders had no influence on study design or on the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication. Publication of the article was not contingent upon approval by the study sponsors. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The NPRD was approved by the ethics committee of the Charite - Universitaetsmedizin Berlin (EA1/044/07). The Biologics in Pediatric Rheumatology Registry (BiKeR) was approved by the ethics committee of the physician board Aerztekammer Nordrhein, Duesseldorf (reference number 2/2015/7441). The COVID-19 Survey was approved by the Ethics Committee of the Technische Universitaet (TU) Dresden (BO-EK-110032020) Parents and patients from the age of 8 years on gave their informed assent/consent for participation. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article.